Loading...
•
Jun 30, 2024
Amphastar Q2 2024 Earnings Report
Amphastar's Q2 2024 performance was marked by solid sales growth, with BAQSIMI® emerging as a key driver.
Key Takeaways
Amphastar Pharmaceuticals reported a strong second quarter with net revenues of $182.4 million, a 25% increase compared to the same period last year. GAAP net income was $37.9 million, or $0.73 per share, while adjusted non-GAAP net income reached $48.7 million, or $0.94 per share. The company's performance was driven by solid sales growth, particularly with BAQSIMI®.
Net revenues for Q2 2024 reached $182.4 million, a 25% increase year-over-year.
GAAP net income for Q2 2024 was $37.9 million, or $0.73 per share.
Adjusted non-GAAP net income for Q2 2024 was $48.7 million, or $0.94 per share.
BAQSIMI® has emerged as a leading driver in the company's portfolio.
Revenue by Segment
Forward Guidance
The company is focused on developing, manufacturing, marketing, and selling technically-challenging generic and proprietary injectable, inhalation, and intranasal products.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...